Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 1/2013

01-01-2013 | Original Article

Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia

Authors: Lucia Catani, Daria Sollazzo, Sara Trabanelli, Antonio Curti, Cecilia Evangelisti, Nicola Polverelli, Francesca Palandri, Michele Baccarani, Nicola Vianelli, Roberto Massimo Lemoli

Published in: Annals of Hematology | Issue 1/2013

Login to get access

Abstract

Along with their immunogenic role, dendritic cells (DCs) are also critical in maintaining tolerance to self-antigens by inducing regulatory T cells (Tregs) via the expression of the immunomodulatory enzyme indoleamine 2,3-dioxygenase 1 (IDO1). In turn, Tregs modulate the maturation and/or function of DCs. In immune thrombocytopenia (ITP), the interaction between DCs and Tregs has never been investigated although decreased number/function of Tregs as well as altered DCs have been described. Here, we ask whether, in ITP: (1) IDO1 expression/activity is decreased in mature DCs; (2) IDO1-mediated Treg generation is impaired; and (3) DC maturation is abnormally modulated by Tregs. We found that in ITP, DCs show reduced capability of upregulating the expression/activity of IDO1. This finding results in the reduced ability of mature DCs of converting T cells into Tregs. In turn, Tregs are characterized by decreased interleukin-10 production and show lower ability of inhibiting DC maturation. In conclusion, these data point out the role of IDO1 in the impaired regulatory T cell development of ITP patients and suggest that the cross-talk between Tregs and DCs is hampered and plays a pathogenetic role.
Appendix
Available only for authorised users
Literature
1.
2.
Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 11:7–13PubMedCrossRef
3.
Campbell DJ, Koch MA (2011) Phenotypical and functional specialization of FoxP3+ regulatory T cells. Nat Rev Immunol 11:119–130PubMedCrossRef
4.
Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 30:1538–1543PubMedCrossRef
5.
Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S (2008) FoxP3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Nat Acad Sci USA 105:10113–10118PubMedCrossRef
6.
Maldonado RA, von Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111–165PubMedCrossRef
7.
Mellor AL, Munn DH (1999) Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation. Immunol Today 20:469–473PubMedCrossRef
8.
Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ (2011) Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 18:2257–2262PubMedCrossRef
9.
Orabona C, Grohmann U (2011) Indoleamine 2,3-dioxygenase and regulatory function: tryptophan starvation and beyond. Methods Mol Biol 677:269–280PubMedCrossRef
10.
Hill M, Tanguy-Royer S, Royer P, Chauveau C, Asghar K, Tesson L, Lavainne F, Rémy S, Brion R, Hubert FX et al (2007) IDO expands human CD4+CD25 high regulatory cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 37:3054–3062PubMedCrossRef
11.
Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC et al (2002) CTLA-4 Ig regulates tryptophan catabolism in vivo. Nat Immunol 3:1097–1101PubMedCrossRef
12.
Chung DJ, Rossi M, Romano E, Ghith J, Yuan J, Munn DH, Young JW (2009) Indoleamine 2,3 dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 114:555–563PubMedCrossRef
13.
Trabanelli S, Ocadlikova D, Evangelisti C, Parisi S, Curti A (2011) Induction of regulatory T cells by dendritic cells through indoleamine 2,3-dioxygenase: a potent mechanism of acquired peripheral tolerance. Curr Med Chem 18:2234–2239PubMedCrossRef
14.
Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, Curti EC, Rutella S, De Cristofaro R, Ottaviani E et al (2010) Indoleamine 2,3 dioxygenase-expressing leukemic dendritic cells impair leukemia specific immune response by inducing potent T regulatory cells. Haematologica 95:2022–2030PubMedCrossRef
15.
16.
Oertelt-Prigione S, Mao TK, Selmi C, Tsuneyama K, Ansari AA, Coppel RL, Coppel RL, Invernizzi P, Podda M, Gershwin ME (2008) Impaired indoleamine 2,3 dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis. Autoimmunity 41:92–99PubMedCrossRef
17.
McMillan R (2007) The pathogenesis of chronic immune thrombocytopenic purpura. Sem Hematol 44(suppl 5):S3–S11CrossRef
18.
Cines DB, Bussel JB, Liebman HA, Luning Prack ET (2009) The ITP syndrome: pathogenic and clinical diversity. Blood 113:6511–6521PubMedCrossRef
19.
20.
Kuwana M, Ikeda Y (2005) The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura. Int J Hematol 81:106–112PubMedCrossRef
21.
Andre S, Tough DF, Lacroix-Desmazes S, Kaveri SV, Bayry J (2009) Surveillance of antigen-presenting cells by CD4+CD25+ regulatory T cells in autoimmunity. Am J Pathol 174:1575–1587PubMedCrossRef
22.
Semple JW, Provan D, Garvey MB, Freedman J (2010) Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 17:590–595PubMedCrossRef
23.
Sakakura M, Wada H, Tawara I, Nobori T, Sugiyama T, Sagawa N, Sakakura SH (2007) Reduced CD4+CD25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120:187–193PubMedCrossRef
24.
Ling Y, Cao X, Yu Z, Ruan C (2007) Circulating dendritic cells subsets and CD4+FoxP3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high dose dexamethasome. Eur J Haematol 79:310–316PubMedCrossRef
25.
Liu B, Zhao H, Poon MC, Han Z, Gu D, Xu M, Jia H, Yang R, Han ZC (2007) Abnormality of CD4+CD25+ regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 78:139–143PubMed
26.
Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K (2008) Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112:1325–1328PubMedCrossRef
27.
Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, Amadori S (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147–1150PubMedCrossRef
28.
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393PubMedCrossRef
29.
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B et al (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168–186PubMedCrossRef
30.
Baecher Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 167:1245–1253PubMed
31.
Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, Preda P, Chirumbolo G, Amabile M, Lemoli RM et al (2006) Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 34:879–884PubMedCrossRef
32.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef
33.
Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21:331–344PubMedCrossRef
34.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 30:775–787CrossRef
35.
Cyetanovich GL, Hafler DA (2010) Human regulatory T cells in autoimmune diseases. Curr Opin Immunol 22:753–760CrossRef
36.
Tadokoro CE, Shakhar G, Shen S, Ding Y, Lino AC, Maraver A, Tadokoro LJJ, Dustin ML (2006) Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 203:505–511PubMedCrossRef
37.
Veldohen M, Moncrieffe H, Hocking RJ, Atkins CJ, Stockinger B (2006) Modulation of dendritic cell function by naïve and regulatory CD4+ T cells. J Immunol 176:6202–6210
38.
Bayry J, Triebel F, Kaveri SV, Tough DF (2007) Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 178:4184–4193PubMed
39.
Kuwana M, Okazaki Y, Ikeda Y (2009) Splenic macrophages maintain autoimmune response via uptake of opsonised platelets in patients with immune thrombocytopenic purpura. J Thromb Haemost 7:322–329PubMedCrossRef
40.
Catani L, Sollazzo D, Ricci F, Polverelli N, Palandri F, Baccarani M, Catani L, Vianelli N, Lemoli RM (2011) The CD47 pathway is deregulated in human immune thrombocytopenia. Exp Hematol 39:486–494PubMedCrossRef
41.
Zhang XL, Peng J, Sun JZ, Liu JJ, Guo CS, Wang ZG, Yu Y, Shi Y, Qin P, Li SG et al (2009) De novo induction of platelet-specific CD4+CD25+ regulatory T cells from CD4+CD25-cells in patients with idiopathic thrombocytopenic purpura. Blood 113:2568–2577PubMedCrossRef
42.
Wang CY, Shi Y, Min YN, Zhu XJ, Guo CS, Peng J, Dong XY, Qin P, Sun JZ, Hou M (2011) Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia. J Clin Immunol 31:643–649PubMedCrossRef
43.
Xu S, Wang C, Zhu X, Dong X, Shi Y, Peng J, Qin P, Sun J, Guo C, Ni H, et al. (2012) Decreased indoleamine 2,3-dioxygenase expression in dendritic cells and role of indoleamine 2,3-dioxygenase-expressing dendritic cells in immune thrombocytopenia. Ann Hematol. doi:10.​1007/​s00277/​012-1451-0
44.
Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM (2005) Regulation of Indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood 105:1574–1581PubMedCrossRef
45.
Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M et al (2010) Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115:3520–3530PubMedCrossRef
46.
Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA (2004) Natural and induced CD4+CD25+ cells educate CD4+CD25-cells to develop suppressive activity: the role of IL-2, TGf-beta and IL-10. J Immunol 172:5213–5221PubMed
47.
Taylor MW, Feng GS (1991) Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516–2522PubMed
48.
Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, Freedman J (1996) Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 87:4245–4254PubMed
49.
Panitsas FP, Theodoropoulou M, Kouraklis A, Karakantza M, Theodorou GL, Zoumbos NC et al (2004) Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 103:2645–2647PubMedCrossRef
50.
Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K et al (2010) Improved regulatory T cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 116:326–336CrossRef
51.
Fujio K, Okamura T, Yamamoto K (2010) The family of IL-10-secreting CD4+ T cells. Adv Immunol 105:99–130PubMedCrossRef
52.
Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Fogli M, Ferri E, Della Cuna GR, Tura S et al (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100:230–237PubMedCrossRef
53.
Frick J-S, Grunebach F, Autenrieth IB (2010) Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. Int J Med Microbiol 300:19–24PubMedCrossRef
Metadata
Title
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia
Authors
Lucia Catani
Daria Sollazzo
Sara Trabanelli
Antonio Curti
Cecilia Evangelisti
Nicola Polverelli
Francesca Palandri
Michele Baccarani
Nicola Vianelli
Roberto Massimo Lemoli
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 1/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1556-5

Other articles of this Issue 1/2013

Annals of Hematology 1/2013 Go to the issue

Original Article

Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma

Original Article

Flow cytometric immunophenotyping is of great value to diagnosis of natural killer cell neoplasms involving bone marrow and peripheral blood

Letter to the Editor

Bendamustine salvage for the treatment of relapsed Hodgkin’s lymphoma after allogeneic bone marrow transplantation

Original Article

Anemia and activities of daily living in the Korean urban elderly population: Results from the Korean Longitudinal Study on Health and Aging (KLoSHA)

Letter to the Editor

Daptomycin nonsusceptible enterococci in hematologic malignancy and hematopoietic stem cell transplant patients: an emerging threat

Original Article

Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits